DSMM	dsmm	O	O
XI	xi	O	O
study	study	O	O
:	:	O	O
dose	dose	O	O
definition	definition	O	O
for	for	O	O
intravenous	intravenous	O	O
cyclophosphamide	cyclophosphamide	S_chemical	O
in	in	O	O
combination	combination	O	O
with	with	O	O
bortezomib/dexamethasone	bortezomib/dexamethasone	S_chemical	O
for	for	O	O
remission	remission	O	O
induction	induction	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
newly	newly	O	O
diagnosed	diagnosed	O	O
myeloma	myeloma	O	O
.	.	O	O

A	a	O	O
clinical	clinical	O	O
trial	trial	O	O
was	was	O	O
initiated	initiated	O	O
to	to	O	O
evaluate	evaluate	O	O
the	the	O	O
recommended	recommended	O	O
dose	dose	O	O
of	of	O	O
cyclophosphamide	cyclophosphamide	S_chemical	O
in	in	O	O
combination	combination	O	O
with	with	O	O
bortezomib	bortezomib	S_chemical	O
and	and	O	O
dexamethasone	dexamethasone	S_chemical	O
as	as	O	O
induction	induction	O	O
treatment	treatment	O	O
before	before	O	O
stem	stem	O	O
cell	cell	O	O
transplantation	transplantation	O	O
for	for	O	O
younger	younger	O	O
patients	patients	O	O
with	with	O	O
newly	newly	O	O
diagnosed	diagnosed	O	O
multiple	multiple	O	B_disease
myeloma	myeloma	O	I_disease
(	(	O	O
MM	mm	O	O
)	)	O	O
.	.	O	O

Thirty	thirty	O	O
patients	patients	O	O
were	were	O	O
treated	treated	O	O
with	with	O	O
three	three	O	O
21-day	21-day	O	O
cycles	cycles	O	O
of	of	O	O
bortezomib	bortezomib	S_chemical	O
1.3	1.3	O	O
mg/m(2	mg/m(2	O	O
)	)	O	O
on	on	O	O
days	days	O	O
1	1	O	O
,	,	O	O
4	4	O	O
,	,	O	O
8	8	O	O
,	,	O	O
and	and	O	O
11	11	O	O
plus	plus	O	O
dexamethasone	dexamethasone	S_chemical	O
40	40	O	O
mg	mg	O	O
on	on	O	O
the	the	O	O
day	day	O	O
of	of	O	O
bortezomib	bortezomib	S_chemical	O
injection	injection	O	O
and	and	O	O
the	the	O	O
day	day	O	O
after	after	O	O
plus	plus	O	O
cyclophosphamide	cyclophosphamide	S_chemical	O
at	at	O	O
900	900	O	O
,	,	O	O
1,200	1,200	O	O
,	,	O	O
or	or	O	O
1,500	1,500	O	O
mg/m(2	mg/m(2	O	O
)	)	O	O
on	on	O	O
day	day	O	O
1	1	O	O
.	.	O	O

The	the	O	O
maximum	maximum	O	O
tolerated	tolerated	O	O
dose	dose	O	O
of	of	O	O
cyclophosphamide	cyclophosphamide	S_chemical	O
was	was	O	O
defined	defined	O	O
as	as	O	O
900	900	O	O
mg/m(2	mg/m(2	O	O
)	)	O	O
.	.	O	O

At	at	O	O
this	this	O	O
dose	dose	O	O
level	level	O	O
,	,	O	O
92	92	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
achieved	achieved	O	O
at	at	O	O
least	least	O	O
a	a	O	O
partial	partial	O	O
response	response	O	O
.	.	O	O

The	the	O	O
overall	overall	O	O
response	response	O	O
rate	rate	O	O
[	[	O	O
complete	complete	O	O
response	response	O	O
(	(	O	O
CR	cr	S_chemical	O
)	)	O	O
plus	plus	O	O
partial	partial	O	O
response	response	O	O
(	(	O	O
PR	pr	O	O
)	)	O	O
]	]	O	O
across	across	O	O
all	all	O	O
dose	dose	O	O
levels	levels	O	O
was	was	O	O
77	77	O	O
%	%	O	O
,	,	O	O
with	with	O	O
a	a	O	O
10	10	O	O
%	%	O	O
CR	cr	S_chemical	O
rate	rate	O	O
.	.	O	O

No	no	O	O
patient	patient	O	O
experienced	experienced	O	O
progressive	progressive	O	B_disease
disease	disease	O	I_disease
.	.	O	O

The	the	O	O
most	most	O	O
frequent	frequent	O	O
adverse	adverse	O	B_disease
events	events	O	I_disease
were	were	O	O
hematological	hematological	O	O
and	and	O	O
gastrointestinal	gastrointestinal	O	O
toxicities	toxicities	O	S_disease
as	as	O	O
well	well	O	O
as	as	O	O
neuropathy	neuropathy	O	S_disease
.	.	O	O

The	the	O	O
results	results	O	O
suggest	suggest	O	O
that	that	O	O
bortezomib	bortezomib	S_chemical	O
in	in	O	O
combination	combination	O	O
with	with	O	O
cyclophosphamide	cyclophosphamide	S_chemical	O
at	at	O	O
900	900	O	O
mg/m(2	mg/m(2	O	O
)	)	O	O
and	and	O	O
dexamethasone	dexamethasone	S_chemical	O
is	is	O	O
an	an	O	O
effective	effective	O	O
induction	induction	O	O
treatment	treatment	O	O
for	for	O	O
patients	patients	O	O
with	with	O	O
newly	newly	O	O
diagnosed	diagnosed	O	O
MM	mm	O	O
that	that	O	O
warrants	warrants	O	O
further	further	O	O
investigation	investigation	O	O
.	.	O	O

